1. Haptoglobin phenotype and levels in type 2 diabetes and effects of fenofibrate
- Author
-
Andrzej S. Januszewski, Hayden K. Young, Kwok‐Leung Ong, Liping Li, Rachel L. O’Connell, Timothy J. Lyons, Clare Kelly, Dessi P. Zaharieva, David R. Sullivan, Russell S. Scott, Anthony C. Keech, Alicia J. Jenkins, and the FIELD Study Investigators
- Subjects
Fenofibrate ,Haptoglobin ,Type 2 diabetes ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
ABSTRACT Aims/Hypothesis In diabetes haptoglobin (Hp) 2 vs Hp 1 allelic product is associated with cardiac and renal complications. Few studies report both Hp phenotype and Hp levels. In a Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial substudy we evaluated the Hp phenotype, Hp levels, and fenofibrate effects. Materials and Methods In 480 adults with type 2 diabetes (T2D) the Hp phenotype was assessed and the Hp level quantified (both using ELISAs assays) in plasma from baseline, after 6 weeks of fenofibrate, and (in n = 200) at 2 years post‐randomization to fenofibrate or placebo. Results The Hp phenotypes 1‐1, 2‐1, and 2‐2 frequencies were 15%, 49%, and 36%, respectively. Baseline Hp levels differed by phenotype (P
- Published
- 2024
- Full Text
- View/download PDF